Search

Search Constraints

You searched for: Author/Creator Brunetta, Paul

Search Results

1. 320. PEDIATRIC OPEN-LABEL CLINICAL STUDY OF RITUXIMAB FOR THE TREATMENT OF GRANULOMATOSIS WITH POLYANGIITIS AND MICROSCOPIC POLYANGIITIS. (29th March 2019)

2. Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Issue 11 (25th September 2019)

3. Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE. Issue 1 (30th March 2015)

4. Autoreactive Plasmablasts After B Cell Depletion With Rituximab and Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Issue 5 (15th March 2023)

5. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Issue 1 (6th October 2021)

6. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Issue 6 (30th November 2015)

7. Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Issue 3 (29th July 2016)

8. Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Issue 7 (July 2017)

9. Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double‐Blind, Phase III Study. Issue 9 (26th August 2013)

10. Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double‐Blind, Phase III Study1. Issue 9 (26th August 2013)